HIV-Infekt pp 349-352 | Cite as

Das Lipodystrophie-Syndrom

  • M. Hartmann
Conference paper

Zusammenfassung

Das Lipodystrophie-Syndrom wurde bei der HIV-Infektion nach Einführung der Pro- teinaseinhibitoren (PI) erstmals beobachtet. Ob diese Störungen durch diese Medika- mentengrupee direkt oder indirekt durch die erfolgreiche Behandlung der HIV-Infektion verursacht wird ist z.Z. unklar. Neben den bekannten Nebenwirkungen der Proteinasein- hibitoren wie gastrointestinale Beschwerden und Interaktionen mit dem Cytochrom P 450-Systemen treten metabolische Veränderungen wie Zucker- und Fettstoffwechsel-störungen meist erst nach einer längeren Therapiedauer auf. An Laborabweichungen werden vorwiegend Triglycerid-, Cholesterin- und Glucoseerhöhungen gesehen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Carr A, Samaras K, Chisholm DJ, Cooper DA (1998) Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 351: 1881–1883PubMedCrossRefGoogle Scholar
  2. 2.
    Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm D J, Cooper DA (1999) Diagnosis and prediction of HIV protease inhibitor (PI)-induced lipodystrophy and impaired glucose tolerance. 6th Conference on Retroviruses and Opportinistic Infections, Chicago, p 641Google Scholar
  3. 3.
    Lo JC, Mulligan K, Tai V W, Algren H, Schambelan M (1998) ≫Buffalo hump≪ in men with HIV-i infection. Lancet 351: 867–870CrossRefGoogle Scholar
  4. 4.
    Kotler DP, Rosenbaum KB, Wang J, Pierson RN (1998) Alterations in body fat distribution in HIV- infected men and women. 12th World AIDS Conference, Genf, pp 336 /32173Google Scholar
  5. 5.
    Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Falloon J (1998) Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 351: 871–875PubMedCrossRefGoogle Scholar
  6. 6.
    Hengel RL, Watts NB, Lennox JL (1997) Benign symmetric lipomatosis associated with protease inhibitors. Lancet, 350: 1596PubMedCrossRefGoogle Scholar
  7. 7.
    Gharakhanian S, Salhi Y, Nguyen TH, Adda N, Catrix S, Vigouroux C, Capeau J, Rozenbaum W (1999) Frequency of Lipodystrophy and Factors Associated with Glucose/Lipid Abnormalities in a Cohort of 650 Patients Treated by Protease Inhibitors. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, p 642Google Scholar
  8. 8.
    Carr A, Samaras K, Burton S, Freund J, Chisholm DJ, Cooper DA (1998) A Syndrome of Peripheral Lipodystrophy (LD), Hyperlipidemia and Insulin Resistance due to HIV Protease Inhibitors (Pi’s). 5th Conference on Retroviruses and Opportunistic Infections, Chicago, p 410Google Scholar
  9. 9.
    Kotler DP, Rosenbaum KB, Wang J, Pierson RN (1998) Alterations in body fat distribution in HIV- infected men and women. 12th World AIDS Conference, Genf: #336/32173Google Scholar
  10. 10.
    Saint-Marc T, Partisani M, Poizot-Martin I, Rouviere O, Touraine JL (1999) A Syndrome of Peripheral Fat Wasting (Lipoatrophy) in Patients Receiving a Nucleoside-Analogue Therapy including D4T. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, p 653Google Scholar
  11. 11.
    Martinez E, Conget I, Lozano L, Casamitjana R, Gatell JM (1999) Reversion of metabolic abnormalities after switching from HIV-i protease inhibitors to nevirapine. AIDS 13: 805–810PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2000

Authors and Affiliations

  • M. Hartmann

There are no affiliations available

Personalised recommendations